ClearBridge All Cap Growth ESG ETF (CACG)
- Previous Close
49.35 - Open
49.78 - Bid 35.52 x 200
- Ask 50.01 x 2000
- Day's Range
49.78 - 50.04 - 52 Week Range
36.97 - 52.68 - Volume
3,156 - Avg. Volume
4,571 - Net Assets 124.87M
- NAV 49.35
- PE Ratio (TTM) 39.49
- Yield 0.30%
- YTD Daily Total Return 4.74%
- Beta (5Y Monthly) 1.07
- Expense Ratio (net) 0.54%
The fund seeks to invest in a diversified portfolio of large, medium and small capitalization stocks that have the potential for above-average long-term earnings and/or cash flow growth and meet its financial and environmental, social and governance (“ESG”) criteria. The fund's subadviser uses a bottom-up investment process that seeks to find inefficiently priced companies with strong fundamentals, incentive-driven management teams, dominant positions in niche markets and/or goods and services that are in high customer demand.
Franklin Templeton Investments
Fund Family
Large Growth
Fund Category
124.87M
Net Assets
2017-05-03
Inception Date
Performance Overview: CACG
Trailing returns as of 4/25/2024. Category is Large Growth.
People Also Watch
Holdings: CACG
Top 10 Holdings (42.45% of Total Assets)
Sector Weightings
Recent News: CACG
Research Reports: CACG
ANIK: Lowering target price to $21.00
ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $21.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetANIK: Lowering target price to $22.00
ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $22.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetANIK: Lowering target price to $25.00
ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $25.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetANIK: Rating decreased to a SELL
ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $28.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target